{"id":"W2162901058","doi":"10.1016/s1470-2045(15)00051-0","title":"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":306,"is_retracted":false,"has_abstract":false,"ca_institutions":"Translational Research in Oncology","funders":"Novartis Pharmaceuticals Corporation","keywords":"Everolimus; Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Breast cancer; Oncology; Response Evaluation Criteria in Solid Tumors; Paclitaxel; Placebo; Cancer; Clinical trial; Phases of clinical research; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001955015,0.002110032,0.0037827,0.0005106498,0.000401344,0.001534022,0.001366138,0.001999286,0.006876017],"category_scores_gemma":[0.001518939,0.0008662059,0.002318077,0.0004941671,0.00138514,0.001772876,0.0005771789,0.004396446,0.001468017],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009297517,"about_ca_system_score_gemma":0.001045478,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001160782,"about_ca_topic_score_gemma":0.003121152,"domain_scores_codex":[0.9994649,0.0002756144,0.00002739131,0.0001052924,0.00003458626,0.00009220523],"domain_scores_gemma":[0.9993445,0.0001718508,0.0001358959,0.00005718069,0.0000286863,0.0002617297],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9787768,0.004434233,0.0003524379,0.0006142916,0.001135787,0.00003248284,0.00005289801,0.0004422448,0.001528244,0.0001036667,0.001013771,0.01151331],"study_design_scores_gemma":[0.9610267,0.03674922,0.0008138993,0.00002812643,0.0003592927,0.00002726593,0.00001547123,0.0002420506,0.000160254,0.00009573939,0.0004689654,0.00001298408],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9781843,0.0112261,0.0007166324,0.00158832,0.001217722,0.002285277,0.001395701,0.0002465476,0.003139379],"genre_scores_gemma":[0.9726847,0.0082117,0.002129836,0.00246384,0.0008704535,0.00303294,0.002453577,0.00007356295,0.008079429],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006876017,"threshold_uncertainty_score":0.02300256,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1072753189955495,"score_gpt":0.4374998133184536,"score_spread":0.330224494322904,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}